Vol. 17 No. 3 (2013)
ANESTHESIOLOGY & RESUSCITATION

Sensitivity of enterobacteriaceae isolated from cardiosurgical patients to antimicrobial chemotherapy

pdf (Русский)
  • V. Ilina,
  • A. Subbotovskaya,
  • V. Kozyreva,
  • D. Sergeevichev,
  • A. Shilova
V. Ilina
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
A. Subbotovskaya
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
V. Kozyreva
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
D. Sergeevichev
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
A. Shilova
Academician E.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
DOI: https://doi.org/10.21688/1681-3472-2013-3-40-44

Published 2013-09-17

Keywords

  • CARBAPENEMS,
  • ENTEROBACTERIACEAE,
  • CTX-M-ENZYMES,
  • MINIMAL INHIBITORY CONCENTRATION,
  • EXTENDED SPECTRUM β-LACTAMASES

How to Cite

Ilina, V., Subbotovskaya, A., Kozyreva, V., Sergeevichev, D., & Shilova, A. (2013). Sensitivity of enterobacteriaceae isolated from cardiosurgical patients to antimicrobial chemotherapy. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 17(3), 40–44. https://doi.org/10.21688/1681-3472-2013-3-40-44

Copyright (c) 2013 Ilina V.N., Subbotovskaya A.I., Kozyreva V.S., Sergeevichev D.S., Shilova A.N.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Data on the sensitivity of enterobacteriaceae isolated from cardiosurgical patients over a period from 2011 to 2012 are analysed in the paper. We studied 124 strains of enterobacteriaceae; the proportion of strains ESBL-producing CTX-M-type was 62.1%. It was found out that from 76.6% to 100% of enterobacteriaceae strains were insensitive to cephalosporins III-IV generation, 62.0% to 72.7% of them were insensitive to the combinations of beta-lactams/beta-lactam inhibitors and 70.1% were insensitive to fluoroquinolones, with high susceptibility to carbapenems (90.9% to ertapenem, imipenem and meropenem 94.8%) and moderate one to aminoglycosides (amikacin 77.9%, netilmicin 72.7%). The reduction of sensitivity to carbapenems is determined by the occurrence of K.pneumoniae, with MIC of ertapenem varying from 2 to 16 ug/ml, MIC of meropenem ranging from 4 to 8 g/ml and MIC of imipenem being equal to 4 ug/ml.

pdf (Русский)

References

  1. Решедько Г.К., Рябкова Е.Л., Кречекова О.И., и др. // Клин. микробиол. антимикроб. химиотер. 2008. Т. 10. № 2. С. 96-117.
  2. Эйдельштейн М.В., Страчунский Л.С., исследовательская группа РОСНЕТ // Клин. микробиол. антимикроб. химиотер. 2005. T. 7. № 4. C. 323-336.
  3. Страчунский Л.С. // Клин. микробиол. антимикроб. химиотер. 2005. Т. 7. № 1. С. 92-96.
  4. Галкин Д.В. // Клин. микробиол. антимикроб. химиотер. 2007. T. 9. № 2. C. 133-152.
  5. Определение чувствительности микроорганизмов к антибактериальным препаратам (Методические указания МУК 4.2.1890_04) // Клин. микробиол. антимикроб. химиотер. 2004. T. 6. № 4. P. 307-359.
  6. CLSI Performance standards for antimicrobial susceptibility testing; Twenty-Second Informational Supplement. 2012. V. 32. № 3.
  7. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, 2013 http: // www.eucast.org
  8. Ejikeugwu P.C., Ugwu C.M., Araka C.O. et al. // International Research Journal Microbiology. 2012. V. 3. № 10. P. 339-344.
  9. Ильина В.Н., Струнин О.В., Соловьев О.Н. и др. // Патология кровообращения и кардиохирургия 2012. № 1. С. 57-60.
  10. Степанова М.Н. // автореферат на соискание ученой степени кандидата биологических наук 2011 г. С. 23.
  11. Girlich D, Laurent L., Nordmann P. et al. // Antimicrob. Agents Chemother. 2009. V. 53. № 2. P. 832-834.
  12. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. // Clinical Infectious Diseases. 2011. V. 53. № 1. P. 60-67.
  13. Ward M.E., Woodford N., Warner M. et al. // Proceedings 15th Eur. Congress Clinical Microbiology infectious Diseases. Copenhagen. 2005. P. 1266.
  14. Woodford N., Dallow J.W.T., Hill R.L.R. // International J. Antimicrobial Agents. 2007. V. 29. P. 456-459.